Effectiveness of a multimodal therapy protocol for the management of allergic rhinitis: a randomized controlled trial

This study endeavors to comprehensively assess the efficacy of a multimodal therapy protocol in the management and treatment of allergic rhinitis.

This study employed a randomized controlled trial design, enrolling a total of 100 patients, who were randomly assigned to either the experimental group (receiving multimodal therapy) or the control group (receiving standard treatment), with 50 patients in each group. All enrolled patients were diagnosed based on standard guidelines for allergic rhinitis. Standardized AR questionnaires were used to assess patients' symptoms. The primary outcome measures included the time of nasal allergy symptom relief and treatment effectiveness. Statistical software will be utilized for data analysis.

The experimental group showed shorter relief times for symptoms such as nasal itching, nasal congestion, rhinorrhea, and sneezing compared to the control group. Specifically, the relief times for nasal itching, nasal congestion, rhinorrhea, and sneezing in the experimental group were (3.16 ± 0.45) days, (2.68 ± 0.55) days, (2.51 ± 0.23) days, and (3.41 ± 0.31) days, respectively, while the control group's respective times were (5.13 ± 0.77) days, (4.35 ± 0.71) days, (4.85 ± 0.63) days, and (6.73 ± 0.99) days (P < 0.05). After treatment, the total effective rate in the experimental group reached 90.0%, significantly higher than the 66.0% in the control group (P < 0.05).

The results of this study indicate that multimodal therapy not only exhibits significant effectiveness in the management of allergic rhinitis but also holds potential advantages in improving patients' quality of life. These findings provide a new perspective for the treatment of AR and may have significant implications for the design and optimization of future AR treatment regimens.